Medical Devices Startups

ProMedix develops the PeriFRL Circulatory Dysfunction Monitor, a device that digitally measures capillary refill time (CRT) to provide standardized, noninvasive monitoring of peripheral perfusion for early sepsis detection and resuscitation. The technology is aimed at clinicians and hospital systems to identify conditions such as septic shock, dehydration, hemorrhage, and cardiogenic shock at the bedside.

1 investor

Promega provides a portfolio of reporter bioassays used to characterize and develop monoclonal antibody and cell-based therapeutics for drug developers. The assays measure biological functions including Fc effector activity, immune checkpoint modulation, T cell activation, and cytokine signaling.

1 investor

Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.

1 investor

ProPharma provides outsourced clinical, regulatory, and quality staffing solutions for pharmaceutical and biotech companies through a flexible staffing partnership (FSP) model. The company supplies experienced professionals from a global network to support drug development and compliance-related functions.

1 investor

PROSION Therapeutics develops platform technology for oncology and other diseases based on research into protein targets like Ena/VASP; the company translates academic research into clinical treatments for conditions with significant patient impact.

1 investor

ProSomnus offers oral appliance devices for treating obstructive sleep apnea and snoring, positioned as an alternative to CPAP machines. The company targets adults with sleep apnea seeking to reduce health risks such as stroke and cardiovascular disease.

1 investor

The Prostate Cancer Foundation is a philanthropic organization that funds life-saving prostate cancer research through grants to leading cancer centers worldwide. It advances treatment options and patient outcomes through scientific research investments.

1 investor

Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases. The company leverages its proprietary technology platform and extensive expertise in drug development, regulatory affairs, and pharmaceutical manufacturing.

1 investor

Protara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.

1 investor

PROTEC develops and manufactures X-ray mechanics and software in Germany, producing complete analog and digital X-ray systems including patient tables, DR upgrades, and detectors. It serves human medicine (radiology) and veterinary practices and clinics, and also supplies film-development machines for industrial material testing.

1 investor

PROTECT3D makes patient-specific 3D-printed braces, splints, orthotics, and protective facemasks created from a smartphone (iPhone) anatomy scan and manufactured in an FDA-certified facility. It serves patients, healthcare providers, and sports teams, including NCAA, NFL, and professional organizations, across foot & ankle, hand & wrist, and sports medicine use cases in the US.

1 investor

Protedyne develops laboratory automation platforms for pharmaceutical, biotech, and diagnostic testing companies to handle high-volume testing with rapid turnaround times. The company applies industrial automation design principles to laboratory equipment serving clinical and research environments.

1 investor

Protomer develops dynamic medicines that modify their activity in the body to increase potency where and when needed. Founded by Caltech alumni and faculty, the company was acquired by Eli Lilly in 2021 and operates as a biotech subsidiary.

1 investor

ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.

1 investor

Protyon develops personalized cancer therapies using computational modeling expertise. The company serves cancer patients and researchers in the biotech and healthcare industry.

1 investor

Provasctec develops a cell therapy combining mesenchymal stem cells with a biodegradable delivery device to create new vascular pathways, with a lead program targeting critical limb ischemia in peripheral artery disease patients. The company operates in regenerative medicine, applying biomaterial engineering and precision cell delivery to conditions including inflammation, cancer, and age-related diseases.

1 investor

Sanofi is a pharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally. The company operates in over 100 countries with a focus on breakthrough science and healthcare innovation.

1 investor

Provepharm is a pharmaceutical company specializing in health-related dyes and colorants, committed to sustainable development and providing quality information on health products to medical professionals. The company operates internationally with French R&D expertise and is a UN Global Compact member.

1 investor

Providien is a contract manufacturer of Class II and Class III finished medical devices, offering thermoforming, precision machining, electromechanical assembly, precision miniature bearings, and medical injection molding. It serves medical device OEMs with turnkey design, build, and validation-to-production services under ISO 9001 and ISO 13485 certifications.

1 investor

Provigate develops a low/non-invasive, low-cost home glucose monitoring service based on weekly glycated albumin (GA) testing from finger-prick blood or saliva samples via mail-in and point-of-care testing, paired with a coaching app and a remote monitoring dashboard for clinicians. It targets people with diabetes and those at risk, aiming to support behavior change for blood-sugar management.

1 investor

Proxima Bio is an early-stage biotechnology company developing protein degradation technology to target previously undruggable proteins for treatment of autoimmune conditions and cancers. The company is spun out of WEHI (Walter and Eliza Hall Institute) and based in Melbourne, Australia.

1 investor

PROXIMED is a home healthcare provider that selects, advises on, and delivers prescribed medical equipment to support patients, seniors, and people with disabilities in staying or returning home safely. It also coordinates home care providers such as nurses, physiotherapists, and personal aides, and supports caregivers in France.

1 investor

Proxisense develops high-performance sensors for monitoring manufacturing processes and diagnostics, with origins in aerospace and defence applications. The company commercializes sensor technologies initially developed for jet engines and oil monitoring.

1 investor

proxSIMity manufactures a modular venipuncture and IV arm simulator with quick-swap patient condition units for clinical training. The product is designed for healthcare institutions to practice peripheral venipuncture and catheter insertion with realistic anatomical and physiological feedback.

1 investor